Barclays cut shares of Puma Biotechnology (NASDAQ:PBYI) from an overweight rating to an equal weight rating in a report published on Thursday, MarketBeat reports. The brokerage currently has $90.00 price target on the biopharmaceutical company’s stock. Several other analysts also recently …
0 Comments